Essential Partners
TRVI icon

Essential Partners’s Trevi Therapeutics TRVI Stock Holding History

Essential Partners’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$158 Hold
11
– – ﹤0.01% 2638
2026
Q2 		$205 Hold
11
– – ﹤0.01% 2633
2026
Q1 		$131 Hold
11
– – ﹤0.01% 2681
2025
Q4 		$138 Hold
11
– – ﹤0.01% 2505
2025
Q3 		$101 Buy
+11
New +$82 ﹤0.01% 2491

Other funds holding TRVI

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
TCOT
Trust Company of Toledo Holland, Ohio $1.25B AUM 28.18% 1-Year Est. Return
PFS Partners
PFS Partners Mine Hill, New Jersey $246M AUM 22.61% 1-Year Est. Return
Harbour Capital Advisors
Harbour Capital Advisors Tysons Corner, Virginia $548M AUM 37.76% 1-Year Est. Return
Chapin Davis
Chapin Davis Baltimore, Maryland $520M AUM 117.57% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
Albion Financial Group
Albion Financial Group Salt Lake City, Utah $1.77B AUM 14.95% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Hilton Head Capital Partners
Hilton Head Capital Partners Hilton Head Island, South Carolina $185M AUM 26.97% 1-Year Est. Return

Essential Partners's TRVI Position: Q3 2026 in Review

Essential Partners held its Trevi Therapeutics (TRVI) position steady in Q3 2026 at 11 shares worth $158. The position accounts for ﹤0.01% of the portfolio, ranked #2638.

Essential Partners first reported a position in TRVI in Q3 2025 and has held it in 5 quarters since. The position peaked at $205 in Q2 2026. 21 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.

  • Essential Partners held 11 shares of Trevi Therapeutics worth $158 as of Q3 2026.
  • Essential Partners left its Trevi Therapeutics share count unchanged in Q3 2026.
  • Trevi Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2638 holding.
  • Essential Partners first reported a position in Trevi Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Essential Partners's Trevi Therapeutics position peaked at $205 in Q2 2026.
  • 21 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.